Mark Oki Sells 50,060 Shares of Achieve Life Sciences (NASDAQ:ACHV) Stock

Achieve Life Sciences, Inc. (NASDAQ:ACHV) CFO Mark Oki sold 50,060 shares of the stock in a transaction that occurred on Thursday, September 18th. The shares were sold at an average price of $2.92, for a total value of $146,175.20. Following the sale, the chief financial officer owned 127,940 shares of the company’s stock, valued at approximately $373,584.80. The trade was a 28.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Achieve Life Sciences Price Performance

Shares of NASDAQ:ACHV opened at $3.04 on Wednesday. The business has a 50 day moving average price of $2.80 and a 200 day moving average price of $2.77. Achieve Life Sciences, Inc. has a twelve month low of $1.84 and a twelve month high of $5.31. The company has a market cap of $155.34 million, a price-to-earnings ratio of -2.08 and a beta of 1.53. The company has a quick ratio of 6.64, a current ratio of 6.64 and a debt-to-equity ratio of 0.21.

Achieve Life Sciences (NASDAQ:ACHV) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, meeting the consensus estimate of ($0.37). Research analysts predict that Achieve Life Sciences, Inc. will post -1.17 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright started coverage on Achieve Life Sciences in a research report on Thursday, August 21st. They issued a “buy” rating and a $12.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating and two have issued a Buy rating to the company’s stock. According to data from MarketBeat.com, Achieve Life Sciences presently has an average rating of “Strong Buy” and an average target price of $14.67.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE lifted its holdings in shares of Achieve Life Sciences by 39.9% in the second quarter. Bank of America Corp DE now owns 33,731 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 9,617 shares in the last quarter. AQR Capital Management LLC bought a new stake in Achieve Life Sciences in the first quarter valued at approximately $32,000. Squarepoint Ops LLC bought a new position in shares of Achieve Life Sciences during the fourth quarter worth approximately $62,000. Manchester Financial Inc. increased its stake in shares of Achieve Life Sciences by 90.8% during the second quarter. Manchester Financial Inc. now owns 46,224 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 22,000 shares during the period. Finally, Sender Co & Partners Inc. bought a new position in shares of Achieve Life Sciences during the second quarter worth approximately $56,000. 33.52% of the stock is currently owned by institutional investors.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.